Antioxidants & cancer
This article was originally published in The Tan Sheet
Participants taking "a combination of selenium, beta-carotene and vitamin E supplements had significantly lower cancer mortality rates than those who did not receive the supplements," Philip Taylor, National Cancer Institute, et al., report in Sept. 17 issue of the Journal of the National Cancer Institute. The General Population Trial in Linxian, China, involved 29,584 stratified participants with an "extraordinarily high" incidence of esophageal and gastric cardia and non-cardia cancers. Researchers found no link between serum beta-carotene levels and cancer risk. "Our findings suggest that alpha-tocopherol and selenium are more likely than beta-carotene to be involved in the reduced cancer rates observed with supplementation during the trial," Taylor et al. conclude...
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.